DCPH Live signaler | Maksimer profitt med Getagraph.com

SELG 115281 min ago

@ $14.50

Utstedt: 13 feb 2024 @ 21:32

Avkastning: 75.03%

Forrige signal: feb 13 - 21:13

Forrige signal: Kjøp

Avkastning: 1.40 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.84M
Gjennomsnittsvolum	1.50M
Markedsverdi	2.09B
EPS	$0 ( 2024-05-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.08
ATR14	$0.00700 (0.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Brightstar Associates Llc	Buy	48 136	Common Stock
2024-04-22	Brightstar Associates Llc	Sell	48 136	Warrants (right to buy)
2024-02-15	Sherman Matthew L	Buy	17 275	Common Stock
2024-02-16	Sherman Matthew L	Sell	2 615	Common Stock
2024-02-15	Sherman Matthew L	Buy	69 100	Stock Option (Right to Buy)

INSIDER POWER
31.23
Last 99 transactions
Buy: 7 012 970 \| Sell: 3 558 980

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: 0.43 (neutral)

Signal:(55.047) Neutral

Deciphera Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
LWACU	0.932
LWAC	0.93
VOSOU	0.922
DFPH	0.91
GSMG	0.91
AGBA	0.88
PPGHU	0.876
MRAC	0.874
BNIXU	0.869
HOTH	0.83

10 Mest negative korrelasjoner
ESAC	-0.928
CTAC	-0.915
MCAE	-0.909
BCYP	-0.895
KURI	-0.857
MACQU	-0.856
MAAC	-0.851
BCYPU	-0.849
CMLT	-0.842
PRSR	-0.835

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Deciphera Pharmaceuticals Korrelasjon - Valuta/Råvare

0.01
( neutral )

0.20
( neutral )

0.00
( neutral )

0.32
( neutral )

0.21
( neutral )

Deciphera Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$163.36M
Bruttogevinst:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2023
Omsetning:	$163.36M
Bruttogevinst:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2022
Omsetning:	$134.04M
Bruttogevinst:	$125.27M (93.46 %)
EPS:	$-2.37

FY	2021
Omsetning:	$96.15M
Bruttogevinst:	$93.22M (96.95 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.